Search
verteporfin (Visudyne)
Tradename: Visudyne.
Indications:
- treatment of age-related macular degeneration predominantly in patients with subfoveal choroidal neovascularization
Dosage:
1) 10.4 mg (6 mg/m2) IV every 3 months PRN
2) IV administration followed by photodynamic laser therapy to activate the drug
Mechanism of action:
- accumulates in abnormal blood vessels of the wet form of macular defeneration
- when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces singlet oxygen & other reactive oxygen species, resulting in local damage to the endothelium & blockage of the vessels
Related
macular degeneration
General
photosensitizing agent (photosensitizer)
Database Correlations
PUBCHEM correlations
References
PubChem: 5362420